EMBC vs UTMD

For growth investors, Embecta Corp.

(EMBC) is the stronger pick with -3. 8% revenue growth year-over-year, versus -5. 8% for Utah Medical Products, Inc. (UTMD). Embecta Corp. (EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Embecta Corp. (EMBC) a "Sell" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Embecta Corp.

(EMBC) is the cheapest at 2. 2x versus Utah Medical Products, Inc. at 18. 5x. On forward P/E, Embecta Corp. is actually cheaper at 1. 3x.

Over the past 5 years, Utah Medical Products, Inc.

(UTMD) delivered a total return of -17. 8%, compared to -87. 6% for Embecta Corp. (EMBC). Over 10 years, the gap is even starker: UTMD returned +19. 1% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus Embecta Corp. 's 1. 31β — meaning EMBC is approximately 137% more volatile than UTMD relative to the S&P 500.

By revenue growth (latest reported year), Embecta Corp.

(EMBC) is pulling ahead at -3. 8% versus -5. 8% for Utah Medical Products, Inc. (UTMD). On earnings-per-share growth, the picture is similar: Embecta Corp. grew EPS 20. 9% year-over-year, compared to -12. 1% for Utah Medical Products, Inc.. Over a 3-year CAGR, EMBC leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus 8. 8% for Embecta Corp. — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus 29. 6% for UTMD. At the gross margin level — before operating expenses — EMBC leads at 62. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Embecta Corp.

(EMBC) trades at 1. 3x forward P/E versus 10. 4x for Utah Medical Products, Inc. — 9. 1x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Embecta Corp. (EMBC) offers the highest yield at 16. 7%, versus 1. 9% for Utah Medical Products, Inc. (UTMD).

For long-horizon retirement investors, Utah Medical Products, Inc.

(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). Both have compounded well over 10 years (UTMD: +19. 1%, EMBC: -87. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EMBC is a small-cap deep-value stock; UTMD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.